Through its discovery platform, Octagon has identified a rate-limiting enzyme involved in central metabolism that drives the rapid proliferation of disease-causing cells. This target has been validated in resistant bacteria and in disease-causing lymphocyte populations and holds significant potential for the development of new medicines.
Effectiveness in Animal Models
OTG005 has demonstrated compelling effectiveness against infections caused by Acinetobacter baumannii and Pseudomonas aeruginosa in animal models and has previously been shown to be safe in humans. Octagon is exploring the potential of this medicine to address resistant pulmonary infections in patients with Cystic Fibrosis. OTG005 is effective against bacteria that are resistant to all other antibiotic classes.